Patients
Molecure develops treatments for diseases with no current cures, focusing on clinical trials to improve patient outcomes.

Molecure is a clinical-stage biotechnology firm developing small molecule drugs for cancer, fibrosis and inflammation.
molecure.comCrawled Nov 11, 2026
Molecure develops treatments for diseases with no current cures, focusing on clinical trials to improve patient outcomes.
Clinical studies OATD-01 and OATD-02, along with mRNA platform
Molecure’s platform designs small molecules targeting RNA, combining bioinformatics, biology, and chemistry to validate mRNA targets and identify binding molecules.
Molecure invites participants to discuss its operational and financial situation, progress in clinical and preclinical programs, and future plans following the Q3 2024 report.
Molecure invites stakeholders to a meeting to discuss progress in clinical trials, development plans, and the company’s 2024 operational and financial situation.
The license covers YKL-40 inhibitors, including OAT-3912, which shows potential in preclinical models for cancers, inflammatory, and fibrotic diseases.
Molecure reduced active projects to five, prioritizing OATD-01 for sarcoidosis and MASH, and OATD-02 for solid tumors.
Molecure focuses its resources on clinical programs OATD-01, OATD-02, and a drug discovery tool, discontinuing its RNA platform development.
The Independent Data Monitoring Committee recommended continuing the Phase II proof-of-concept study for pulmonary sarcoidosis without protocol changes, based on safety and efficacy data from 30 patients.
Molecure offers opportunities to join its team of experts.
OncoArendi Therapeutics hired Dr. Timi Oshodi as Director of Preclinical Development to oversee preclinical safety and pharmacokinetic studies.
Dr. Zbigniew Zasłona, a biologist specializing in pulmonary diseases, has joined OncoArendi Therapeutics S.A. research team after serving as a Senior Investigator at Sitryx.
Dr. Piotr Iwanowski holds a medical degree and a PhD in medical sciences. He has over 20 years of experience supporting global clinical development in leadership and executive roles, including as Chief Medical Officer.
Piotr Lutostański is an economist with over 20 years of experience in macroeconomics, corporate strategy, risk management, and investment management. He serves as CEO of FTF Columbus, a Supervisory Board Member of Barlinek S.A., and Chief Economist of Michał Sołowow’s Capital Group.
Piotr Lutostański is a senior executive with expertise in macroeconomics, corporate strategy, risk management, and investment management. He currently leads FTF Columbus, serves on Barlinek S.A.’s Supervisory Board, and acts as Chief Economist for Michał Sołowow’s Capital Group.
Molecure partners with leading research institutions to advance oncology, fibrotic, and inflammatory disease treatments using its expertise in small-molecule drug discovery.
Molecure is a biotechnology company discovering and developing drugs for previously incurable diseases.
Molecure’s **KITE clinical trial (OATD-01 program)** receives an **Independent Data Monitoring Committee (IDMC) recommendation** to proceed without altering the study protocol. The biotech firm develops first-in-class small-molecule therapies targeting incurable diseases by modulating protein activity. The IDMC’s decision follows review of interim trial data, signaling continued confidence in the program’s design.
Molecure S.A. discontinues its RNA research program and halts further development in this area. The biotech company specializes in discovering first-in-class small-molecule drugs targeting protein activity for treating incurable diseases. This shift refocuses efforts on projects deemed most commercially viable.
Molecure reports progress in its clinical programs **OATD-01** and **OATD-02**, accelerating research and development efforts in 2024. The company highlights key milestones achieved, though specific details on trial outcomes or timelines remain unspecified. Molecure focuses on advancing its pipeline of innovative therapies through these two lead projects.
Molecure and Ocean Biomedical have entered an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. The deal includes the lead molecule **OAT-3912**, which demonstrates preclinical potential in treating cancers, inflammatory, and fibrotic diseases. The license also covers a patent-pending molecular screening test to advance the program and support future inhibitor development.
Molecure refocuses its pipeline on two clinical-stage therapies, **OATD-01 and OATD-02**, targeting inflammatory and fibrotic diseases. The company reduces its discovery-phase programs from five to three, prioritizing these projects after demonstrating progress in clinical trials. Molecure’s approach combines small-molecule drugs and mRNA modulation to address previously untreatable conditions.
Molecure initiates the OATD-01 Phase 2 clinical trial in the UK, dosing the first patient with pulmonary sarcoidosis. The study, named KITE, evaluates the safety and efficacy of Molecure’s investigational therapy. This marks a key step in advancing treatment options for patients with this rare lung disease.